Table 2 ART adherence, mental health, stigma and discrimination, and quality of life of participants at baseline and endline in CAD and MMD arms

From: Impact of a community-based antiretroviral therapy delivery model for people living with HIV in Cambodia

 

Baseline

Endline

 

CAD1 (n = 1626) n (%)

MMD2 (n = 1441) n (%)

P value

CAD (n = 1626) n (%)

MMD (n = 1441) n (%)

P value

ART adherence

Self-reported ART adhered

1415 (87)

1301 (90.3)

0.005

1412 (86.8)

1216 (84.4)

0.05

HIV-related Stigma (People Living with HIV Stigma Index)

Non-stigma experienced

1499 (92.2)

1362 (94.5)

0.01

1503 (92.4)

1315 (91.3)

0.23

Low internal stigma

1122 (69)

914 (63.4)

0.001

1305 (80.3)

1053 (73.1)

<0.001

Not fear of stigma

1445 (88.9)

1234 (85.6)

0.01

1475 (90.7)

1281 (88.9)

0.10

Mental health status (CES-D)

No depression symptoms

1263 (77.7)

1208 (83.8)

<0.001

1182 (72.7)

1030 (71.5)

0.45

Quality of life (SF-12)

Good mental health

1241 (76.3)

1213 (84.2)

<0.001

1261 (77.6)

1183 (82.1)

0.002

Good physical health

887 (54.6)

1004 (69.7)

<0.001

806 (49.6)

745 (51.7)

0.24

  1. Values are n (%) unless otherwise indicated. Differences between study arms were evaluated using Pearson’s χ2 tests (two-sided) for categorical variables. No adjustments for multiple comparisons were applied as this table reports descriptive outcome distributions. Exact p values are shown.
  2. ART antiretroviral therapy, CAD community-based ART delivery, CES-D Center for Epidemiologic Study Depression Scale, MMD multi-month dispensing, SF-12 12-item Short Form survey.